HIV治療薬の市場規模、シェア、動向、予測：薬剤クラス別、流通チャネル別、地域別、2025～2033年

HIV治療薬の世界市場規模は、2024年に328億5,000万米ドルとなりました。今後、IMARC Groupは、同市場が2033年までに450億7,000万米ドルに達し、2025～2033年にかけて3.40%のCAGRを示すと予測しています。現在、北米が市場を独占しており、2024年には45.7％を超える大きな市場シェアを占めています。HIV治療薬市場シェアは、HIV/AIDSに対する認識と予防努力の高まり、世界のHIV/AIDS有病率の増加、より効果的で利用しやすい抗レトロウイルス療法に焦点を当てた様々な研究開発の進行により、着実な成長を遂げています。

様々な組織が、膨大な量の構造化・非構造化データを活用して意思決定を行い、顧客体験を向上させ、業務を強化することの重要性を認識しつつあります。ビッグデータの利用拡大、AIや機械学習技術の革新、クラウドコンピューティングの利用領域の拡大が、この動向をさらに高めています。さらに、さまざまな産業におけるデータ主導の意思決定に対する需要の高まりが、HIV治療薬の需要を促進しています。そのほか、デジタルトランスフォーメーションプロジェクトの増加や、競争圧力や市場ニーズの変化に対応するためのリアルタイム分析への需要が、市場成長の主要促進要因となっています。

米国は、分析がオペレーションの最適化と戦略立案に極めて重要である多様なセグメントで、デジタルトランスフォーメーションへの取り組みが広がっていることを背景に、主要な市場破壊者として際立っています。防衛セグメントにおける先進技術の導入に向けた取り組みの増加は、HIV治療薬市場の成長に新たな成長の道を開いています。例えば、米国国防総省は2024年7月、シンガポール国防省とデータ、分析、人工知能の協力に関する意向表明（SOI）に署名しました。このSOIは、技術協力のための包括的な手法を導入するもので、両国の国防省は、データ、分析、AI能力をスピードとスケールで活用するためのアプローチを検討し、ベストプラクティスを議論することができます。

HIV治療薬市場動向

HIV/AIDSの蔓延拡大

HIV/AIDSの世界的流行は依然として公衆衛生上の重大な問題であり、産業レポートによると、2021年時点で世界で約3,800万人がHIVとともに生活しています。この蔓延の増加は、HIV治療薬の需要を直接的に促進します。特に予防対策へのアクセスが限られている地域では、新たな感染者が出続けており、効果的な治療オプションの必要性が高まっています。特にサハラ以南のアフリカやアジア、東欧の一部地域ではHIVの感染率が高いため、HIV治療薬の要である抗レトロウイルス療法（ART）の持続的な普及が必要です。

治療法の進歩

近年、HIV治療薬レジメンが大きく進歩し、HIV治療薬市場の成長に寄与しています。複数の抗レトロウイルス薬を組み合わせた高活性抗レトロウイルス療法（HAART）の開発は、HIV治療薬に革命をもたらしました。これらの進歩は、HIV治療薬の有効性を向上させただけでなく、副作用を減少させ、患者のアドヒアランスと治療成績の向上につながりました。インテグラーゼ阻害剤のような新しい薬剤クラスの導入や長時間作用型注射薬の開発により、治療選択肢はさらに広がり、患者の多様なニーズや嗜好に対応できるようになりました。たとえば2024年、ギリアド社はHIVグラスゴーで、HIV予防のための年2回投与レナカパビルに関する第3相PURPOSE 2検査の完全な結果を発表しました。この調査では、レナカパビルがHIV感染を96％減少させ、トルバダを上回ったことが実証されました。このような市場の開拓は、治療効果を高め、患者のコンプライアンスを向上させ、継続的なHIV治療薬市場の成長を支えています。

患者の意識の高まり

HIV治療薬市場を牽引する主要因は、患者における認知度と診断率の上昇です。たとえばインドでは、国家エイズ対策計画（NACP）が2020～21年の間に約4,800万件のHIV検査を実施し、その中には妊婦の2,480万件の検査も含まれています。2022～23年の最初の6ヵ月間では、約3,100万件のHIV検査が実施され、2022～23年の全期間では6,000万件以上の検査が実施されると予測されています。この検査数の増加により、診断され、その後治療を受ける人の数が増加しています。2022年9月現在、インドで抗レトロウイルス（ARV）治療を受けているHIV感染者は約162万4,000人で、前年から11万人増加しました。公衆衛生キャンペーンや教育的取り組みにより、HIV/AIDSに対する理解が深まり、偏見が薄れ、検査を受ける人が増えました。また、早期診断技術の向上もHIVの発見率を高め、治療を受ける人の増加に寄与しています。このような診断率の上昇と、特に有病率の高い地域でHIV検査を改善するための継続的な取り組みとが相まって、効果的なHIV治療薬への需要が引き続き高まっています。

併用療法への注目の高まり

併用療法はHIV治療薬の標準となっており、複数の抗レトロウイルス薬を使用することで有効性を高め、薬剤耐性を防止しています。合剤（FDC）の開発と承認により、治療レジメンが簡素化され、アドヒアランスと患者の転帰が改善されました。製薬会社は、錠剤の負担軽減や患者のコンプライアンス向上など、単剤療法と比較していくつかの利点があるこれらの併用療法の開発にますます注力しています。主要企業であるギリアド・サイエンシズ社は、併用療法であるビクタビーの売上が好調であると報告しています。2024年第4四半期、ビクタビーは38億米ドルの売上を達成し、前年比21％増となりました。この成長は、ギリアド社の同四半期のHIV治療薬売上高合計76億米ドルに貢献しました。ヘルスケアプロバイダと患者の間で併用療法への嗜好が高まっていることは、HIV治療薬市場の展望を明るくする重要な要因です。

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要産業動向

第5章 世界のHIV治療薬市場

• 市場概要
• 市場実績
• COVID-19の影響
• 価格分析
• 市場内訳：薬剤クラス別
• 市場内訳：流通チャネル別
• 市場内訳：地域別
• 市場予測
• SWOT分析
• バリューチェーン分析
• ポーターのファイブフォース分析

第6章 市場内訳：薬剤クラス別

• ヌクレオシド逆転写酵素阻害剤
• マルチクラスの組み合わせ製品
• プロテアーゼ阻害剤
• HIVインテグラーゼ鎖転移阻害剤
• 非ヌクレオシド系逆転写酵素阻害剤
• エントリー阻害剤-CCR5共受容体拮抗薬
• 融合阻害剤など

第7章 市場内訳：流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局
• その他

第8章 市場内訳：地域別

• 北米
• 欧州
• アジア太平洋
• 中東・アフリカ
• ラテンアメリカ

第9章 HIV治療薬製造プロセス

• 製品概要
• 原料の要件
• 製造プロセス
• 主要成功要因とリスク要因

第10章 競合情勢

• 市場構造
• 市場内訳：主要企業別
• 主要企業のプロファイル
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • ViiV Healthcare
  • AbbVie
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Cipla Limited
  • Daiichi Sankyo
  • Emcure
  • Hetero Drugs
  • Mylan

List of Figures

• Figure 1: Global: HIV Drugs Market: Major Drivers and Challenges
• Figure 2: Global: HIV Drugs Market: Sales Value (in Billion USD), 2019-2024
• Figure 3: Global: HIV Drugs Market: Breakup by Drug Class (in %), 2024
• Figure 4: Global: HIV Drugs Market: Breakup by Distribution Channel (in %), 2024
• Figure 5: Global: HIV Drugs Market: Breakup by Region (in %), 2024
• Figure 6: Global: HIV Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
• Figure 7: Global: HIV Drugs Industry: SWOT Analysis
• Figure 8: Global: HIV Drugs Industry: Value Chain Analysis
• Figure 9: Global: HIV Drugs Industry: Porter's Five Forces Analysis
• Figure 10: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 11: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 12: Global: HIV Drugs (Multi-Class Combination Products) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 13: Global: HIV Drugs (Multi-Class Combination Products) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 14: Global: HIV Drugs (Protease Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 15: Global: HIV Drugs (Protease Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 16: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 17: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 18: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 19: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 20: Global: HIV Drugs (Entry Inhibitors - CCR5 Co-Receptor Antagonist) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 21: Global: HIV Drugs (Entry Inhibitors - CCR5 Co-Receptor Antagonist) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 22: Global: HIV Drugs (Fusion Inhibitors and Others) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 23: Global: HIV Drugs (Fusion Inhibitors and Others) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 24: Global: HIV Drugs Market: Sales through Hospital Pharmacies (in Million USD), 2019 & 2024
• Figure 25: Global: HIV Drugs Market Forecast: Sales through Hospital Pharmacies (in Million USD), 2025-2033
• Figure 26: Global: HIV Drugs Market: Sales through Retail Pharmacies (in Million USD), 2019 & 2024
• Figure 27: Global: HIV Drugs Market Forecast: Sales through Retail Pharmacies (in Million USD), 2025-2033
• Figure 28: Global: HIV Drugs Market: Sales through Online Pharmacies (in Million USD), 2019 & 2024
• Figure 29: Global: HIV Drugs Market Forecast: Sales through Online Pharmacies (in Million USD), 2025-2033
• Figure 30: Global: HIV Drugs Market: Sales through Other Distribution Channels (in Million USD), 2019 & 2024
• Figure 31: Global: HIV Drugs Market Forecast: Sales through Other Distribution Channels (in Million USD), 2025-2033
• Figure 32: North America: HIV Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 33: North America: HIV Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 34: Europe: HIV Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 35: Europe: HIV Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 36: Asia Pacific: HIV Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 37: Asia Pacific: HIV Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 38: Middle East and Africa: HIV Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 39: Middle East and Africa: HIV Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 40: Latin America: HIV Drugs Market: Sales Value (in Million USD), 2019 & 2024
• Figure 41: Latin America: HIV Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 42: HIV Drugs Manufacturing: Detailed Process Flow
• Figure 43: Global: HIV Drugs Market: Breakup by Key Players (in %)

List of Tables

• Table 1: Global: HIV Drugs Market: Key Industry Highlights, 2024 and 2033
• Table 2: Global: HIV Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
• Table 3: Global: HIV Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
• Table 4: Global: HIV Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
• Table 5: HIV Drugs Manufacturing: Raw Material Requirements
• Table 6: Global: HIV Drugs Market: Competitive Structure
• Table 7: Global: HIV Drugs Market: Key Players

The global HIV drugs market size was valued at USD 32.85 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 45.07 Billion by 2033, exhibiting a CAGR of 3.40% during 2025-2033. North America currently dominates the market, holding a significant market share of over 45.7% in 2024. The HIV drugs market share is experiencing steady growth due to the increasing awareness and prevention efforts, growing prevalence of HIV/AIDS across the globe, and ongoing various research and development initiatives focused on more effective and accessible antiretroviral therapies.

Various organizations are identifying the significance of leveraging vast volumes of structured and unstructured data to make decisions, enhance customer experience, and enhance operations. Growing use of big data, innovations in AI and machine learning technologies, and broadening use areas of cloud computing have further increased this trend. Additionally, increased demand for data-driven decision-making across various industries is driving the HIV drugs demand. Besides, the growth in digital transformation projects and the demand for real-time analytics to respond to competitive pressures and changing market needs are the major drivers of the growth of the market.

The United States stands out as a key market disruptor, driven by widespread digital transformation initiatives across diverse sectors where analytics is pivotal for operational optimization and strategic planning. The increasing initiatives for implementing advanced technologies in the defense sector are opening new growth avenues for the HIV drugs market growth. For instance, in July 2024, The United States Department of Defense signed a Statement of Intent (SOI) for data, analytics, and artificial intelligence cooperation with the Singapore Ministry of Defense. The SOI deploys a holistic method for technological collaboration, allowing both defense establishments to examine approaches and discuss the best practices for leveraging data, analytics, and AI capabilities at speed and scale.

HIV Drugs Market Trends:

Growing Prevalence of HIV/AIDS

The global HIV/AIDS epidemic remains a critical public health issue, with approximately 38 million people living with HIV worldwide as of 2021, according to an industry report. This increased prevalence directly drives the demand for HIV drugs. As new cases continue to emerge, especially in regions with limited access to preventive measures, the need for effective treatment options intensifies. The high transmission rate of HIV, particularly in sub-Saharan Africa and certain parts of Asia and Eastern Europe, necessitates sustained and increased availability of antiretroviral therapy (ART), which remains the cornerstone of HIV treatment.

Advancements in Treatments

Recent years have witnessed significant advancements in HIV treatment regimens, contributing to the growth of the HIV drugs market. The development of highly active antiretroviral therapy (HAART), which combines multiple antiretroviral drugs, has revolutionized HIV treatment. These advancements have not only improved the effectiveness of HIV drugs but also reduced side effects, leading to better patient adherence and outcomes. The introduction of newer drug classes like integrase inhibitors and the development of long-acting injectables have further expanded treatment options, catering to diverse patient needs and preferences. For example, in 2024, Gilead shared complete Phase 3 PURPOSE 2 trial results on twice-yearly lenacapavir for HIV prevention at HIV Glasgow. The research demonstrated lenacapavir lowered HIV infections by 96%, beating Truvada. These developments increase treatment effectiveness and also enhance patient compliance, underpinning ongoing HIV drugs market growth.

Increasing Awareness Among Patients

Rising awareness and diagnostic rates among patients represent the primary factor driving the HIV drugs market. In India, for instance, the National AIDS Control Programme (NACP) conducted approximately 48 million HIV tests in the 2020-21 period, including 24.8 million tests among pregnant women. In the first six months of 2022-23, around 31 million HIV tests were undertaken, with projections indicating that more than 60 million tests would be conducted during the entire 2022-23 period-the highest since the program's inception. This increase in testing has led to a rise in the number of individuals diagnosed and subsequently seeking treatment. As of September 2022, approximately 1.624 million people living with HIV (PLHIV) in India were on antiretroviral (ARV) treatment, an increase of 110,000 from the previous year. Public health campaigns and educational initiatives have increased the understanding of HIV/AIDS, reducing stigma and encouraging more people to get tested. Early and improved diagnostic techniques have also contributed to higher detection rates of HIV, subsequently increasing the number of individuals seeking treatment. This rise in diagnosis, coupled with ongoing efforts to improve HIV testing, particularly in regions with high prevalence rates, continues to fuel the demand for effective HIV medications.

Rising Focus on Combination Therapies

Combination therapies have become a standard in HIV treatment, involving the use of multiple antiretroviral drugs to enhance efficacy and prevent drug resistance. The development and approval of fixed-dose combinations (FDCs) have simplified treatment regimens, improving adherence and patient outcomes. Pharmaceutical companies are increasingly focusing on developing these combination therapies, which offer several advantages over monotherapy, including reduced pill burden and improved patient compliance. Gilead Sciences, a leading pharmaceutical company, reported robust sales of its combination therapy, Biktarvy. In the fourth quarter of 2024, Biktarvy achieved sales of USD 3.8 billion, marking a 21% increase from the previous year. This growth contributed to Gilead's total HIV drug revenue of USD 7.6 billion for the quarter. The growing preference for combination therapies among healthcare providers and patients is a key factor providing a positive HIV drugs market outlook.

HIV Drugs Industry Segmentation:

Analysis by Drug Class:

• Nucleoside Reverse Transcriptase Inhibitors
• Multi-Class Combination Products
• Protease Inhibitors
• HIV Integrase Strand Transfer Inhibitors
• Non-Nucleoside Reverse Transcriptase Inhibitors
• Entry Inhibitors - CCR5 Co-Receptor Antagonist
• Fusion Inhibitors and Others

Nucleoside reverse transcriptase inhibitors lead the market with around 43.2% of market share in 2024. NRTIs, also known as nucleoside analogs, are a crucial class of HIV drugs. They inhibit the action of reverse transcriptase, an enzyme the virus uses to replicate its genetic material. NRTIs are often included as a backbone in HIV treatment regimens due to their effectiveness and safety. They are widely used as a first-line therapy, either alone or in combination with other drug classes, making them the largest segment in the HIV drugs market.

Multi-class combination products refer to antiretroviral therapies that combine drugs from different classes. These combinations are designed to target HIV from multiple angles, reducing the risk of resistance development and increasing treatment efficacy. They offer convenience by simplifying the regimen for patients and are often prescribed when NRTIs alone are insufficient.

Protease inhibitors (PIs) interfere with the protease enzyme, necessary for HIV maturation and replication. PIs are a vital part of combination therapies and have been instrumental in reducing HIV-related deaths. They are used in conjunction with other drug classes to suppress viral replication effectively.

Integrase strand transfer inhibitors (INSTIs) block the integration of viral genetic material into the host cell's DNA, preventing viral replication. INSTIs have gained prominence due to their potent antiviral activity and favorable side-effect profiles. They are commonly used in first-line regimens and in treatment-experienced patients.

NNRTIs are another class of HIV drugs that target reverse transcriptase but do so differently from NRTIs. They bind to the enzyme and inhibit its activity. NNRTIs are often part of combination therapies and are especially useful in cases where resistance to other drug classes has developed.

CCR5 co-receptor antagonists block the CCR5 receptor on the surface of immune cells, preventing HIV from entering and infecting these cells. They are typically used in patients who are CCR5-tropic, meaning their virus uses the CCR5 co-receptor for entry.

Fusion inhibitors work by preventing the virus from fusing with the host cell membrane, thus inhibiting viral entry. This class of drugs is less commonly used than others due to their complex administration (usually by injection).

Analysis by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Hospital pharmacies lead the market with around 49.5% of market share in 2024. Hospital pharmacies constitute the largest segment in the HIV drugs market, primarily due to their role as essential providers of antiretroviral therapies to inpatients and outpatients living with HIV/AIDS. These pharmacies operate within healthcare institutions, including public and private hospitals, clinics, and specialty HIV treatment centers. They offer a wide range of HIV medications, ensuring access to the latest antiretroviral therapies for patients. Hospital pharmacies play a crucial role in medication management, counseling, and monitoring, contributing significantly to patient adherence and treatment outcomes. With a direct link to healthcare providers, hospital pharmacies are pivotal in the comprehensive care and management of HIV/AIDS patients.

Retail pharmacies, including independent drugstores and chain pharmacies, form another vital segment in the HIV drugs market. They serve as accessible points of care for individuals seeking prescription medications, including antiretroviral drugs. Retail pharmacies provide convenience and privacy for patients picking up their HIV medications. They play a critical role in supporting medication adherence through counseling and refill reminders. The retail segment is especially important for patients in urban and suburban areas who may not access hospital-based care regularly.

Online pharmacies have gained prominence as a convenient and discrete source of HIV medications. This segment caters to individuals who prefer the convenience of ordering their antiretroviral drugs online and having them delivered to their doorstep. Online pharmacies offer a wide selection of HIV medications, often at competitive prices. They may also provide telemedicine services, enabling patients to consult with healthcare professionals remotely. The online pharmacy segment has seen significant growth, particularly in regions with robust e-commerce infrastructure, and it serves as an option for individuals who face barriers to traditional pharmacy access.

Regional Analysis:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

In 2024, North America accounted for the largest market share of over 45.7%. North America dominates the global HIV drugs market due to its well-developed healthcare infrastructure, high awareness about HIV/AIDS, and access to advanced antiretroviral therapies. The region is characterized by extensive research and development activities, a large patient population, and significant government funding for HIV/AIDS programs. Furthermore, the presence of major pharmaceutical companies in North America contributes to the market's growth. The focus here is on innovative treatments, combination therapies, and efforts to reduce new infections through comprehensive prevention strategies.

Europe is a substantial market for HIV drugs, characterized by a well-regulated healthcare system and access to state-of-the-art treatments. The region has made progress in reducing HIV transmission rates, but it continues to face challenges related to stigma and late diagnosis. The market in Europe is driven by increasing awareness, comprehensive healthcare coverage, and collaborations between healthcare providers and pharmaceutical companies to improve patient outcomes. Additionally, research into long-acting therapies and preventive measures like PrEP contributes to the market's development.

The Asia Pacific region is witnessing rapid growth in the HIV drugs market due to its large and diverse population, including many individuals living with HIV. This segment faces unique challenges, such as varying healthcare infrastructure, economic disparities, and culturally diverse populations. Increased efforts to expand access to treatment, raise awareness, and reduce new infections are driving market growth. Generic medications and government initiatives to combat HIV/AIDS play a significant role in the Asia Pacific market. Moreover, collaborations with international organizations and NGOs are enhancing the region's response to the HIV epidemic.

Latin America has a growing HIV drugs market, driven by the expanding healthcare infrastructure and increased access to treatment and prevention programs. The region faces challenges related to inequality and limited access to healthcare services in some areas. However, initiatives to improve healthcare coverage, raise awareness, and expand access to antiretroviral therapies are driving market growth. Collaboration between governments, pharmaceutical companies, and non-profit organizations is critical to addressing the HIV/AIDS epidemic in Latin America.

The Middle East and Africa represent a diverse and challenging market for HIV drugs. While access to treatment has improved in some countries, significant disparities persist due to economic and healthcare infrastructure differences. The region faces cultural and social stigma related to HIV/AIDS, which can hinder diagnosis and treatment. Nonetheless, efforts to expand access to medications, increase awareness, and promote preventive measures are ongoing. Partnerships with international organizations and global health initiatives are crucial in addressing the unique challenges in the Middle East and Africa.

Competitive Landscape:

Key players in the global HIV drugs market are actively engaged in several strategic initiatives. They are focusing on research and development to innovate and improve existing antiretroviral therapies, aiming for more convenient dosing regimens, fewer side effects, and enhanced treatment outcomes. These companies are also expanding their product portfolios by developing new drugs and combination therapies. Additionally, they are collaborating with governments, NGOs, and healthcare providers to increase access to HIV medications in resource-limited regions and to implement preventive measures. Furthermore, these pharmaceutical giants are investing in awareness campaigns and education to reduce HIV stigma and promote early diagnosis and treatment.

The report provides a comprehensive analysis of the competitive landscape in the HIV drugs market with detailed profiles of all major companies, including:

• Boehringer Ingelheim International GmbH
• Merck & Co., Inc.
• ViiV Healthcare
• AbbVie
• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb
• Gilead Sciences, Inc.
• Johnson & Johnson
• Cipla Limited
• Daiichi Sankyo
• Emcure Pharmaceuticals
• Hetero Drugs
• Mylan N.V

Key Questions Answered in This Report

• 1.How big is the HIV drugs market?
• 2.What is the future outlook of HIV drugs market?
• 3.What are the key factors driving the HIV drugs market?
• 4.Which region accounts for the largest HIV drugs market share?
• 5.Which are the leading companies in the global HIV drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global HIV Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Price Analysis
• 5.5 Market Breakup by Drug Class
• 5.6 Market Breakup by Distribution Channel
• 5.7 Market Breakup by Region
• 5.8 Market Forecast
• 5.9 SWOT Analysis
  • 5.9.1 Overview
  • 5.9.2 Strengths
  • 5.9.3 Weaknesses
  • 5.9.4 Opportunities
  • 5.9.5 Threats
• 5.10 Value Chain Analysis
  • 5.10.1 Overview
  • 5.10.2 Research and Development
  • 5.10.3 Raw Material Procurement
  • 5.10.4 Manufacturing
  • 5.10.5 Marketing
  • 5.10.6 Distribution
  • 5.10.7 End-Use
• 5.11 Porters Five Forces Analysis
  • 5.11.1 Overview
  • 5.11.2 Bargaining Power of Buyers
  • 5.11.3 Bargaining Power of Suppliers
  • 5.11.4 Degree of Competition
  • 5.11.5 Threat of New Entrants
  • 5.11.6 Threat of Substitutes

6 Market Breakup by Drug Class

• 6.1 Nucleoside Reverse Transcriptase Inhibitors
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Multi-Class Combination Products
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Protease Inhibitors
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 HIV Integrase Strand Transfer Inhibitors
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Non-Nucleoside Reverse Transcriptase Inhibitors
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Entry Inhibitors - CCR5 Co-Receptor Antagonist
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Fusion Inhibitors and Others
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast

7 Market Breakup by Distribution Channel

• 7.1 Hospital Pharmacies
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Retail Pharmacies
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Online Pharmacies
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Europe
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Asia Pacific
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Middle East and Africa
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Latin America
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 HIV Drugs Manufacturing Process

• 9.1 Product Overview
• 9.2 Raw Material Requirements
• 9.3 Manufacturing Process
• 9.4 Key Success and Risk Factors

10 Competitive Landscape

• 10.1 Market Structure
• 10.2 Market Breakup by Key Players
• 10.3 Profiles of Key Players
  • 10.3.1 Boehringer Ingelheim International GmbH
  • 10.3.2 Merck & Co., Inc.
  • 10.3.3 ViiV Healthcare
  • 10.3.4 AbbVie
  • 10.3.5 F. Hoffmann-La Roche Ltd.
  • 10.3.6 Teva Pharmaceutical Industries Ltd.
  • 10.3.7 Bristol-Myers Squibb
  • 10.3.8 Gilead Sciences, Inc.
  • 10.3.9 Johnson & Johnson
  • 10.3.10 Cipla Limited
  • 10.3.11 Daiichi Sankyo
  • 10.3.12 Emcure
  • 10.3.13 Hetero Drugs
  • 10.3.14 Mylan